Shawn Kwatra, M.D., reveals new OX40 ligand therapies for atopic dermatitis, promising new hope for patients at the Fall Clinical Dermatology meeting.
Shawn Kwatra addresses the complexities of atopic dermatitis and prurigo nodularis at the Fall Clinical Dermatology Conference, emphasizing tailored treatment strategies.
Elacestrant significantly improved progression-free survival and maintained a manageable safety profile, especially benefiting patients with ESR1-mutated tumors.
The phase 3 randomized trial enrolled 694 patients with ER+/HER2– disease, stratified by ESR1 mutation status and prior therapies, to compare elacestrant versus standard-of-care endocrine treatments.
An expert discusses how albuminuria and declining estimated glomerular filtration rate (eGFR) serve as vital early biomarkers for kidney and cardiovascular health, stressing the importance of regular testing and early intervention to prevent disease progression and improve patient outcomes.
New findings reveal aflibercept 8 mg enhances vision and extends injection intervals for nAMD and DME patients, reducing treatment burden significantly.
Panelists discuss how the GALAXI trials’ limitations include exclusion of patients with penetrating/stricturing disease and perianal fistulizing disease and pediatric populations, while emphasizing key takeaways for different stakeholders: Patients can expect strong symptomatic relief with endoscopic healing and excellent safety, providers gain a rigorously-tested first-line treatment option with evidence-based positioning in treatment algorithms and payers should recognize the high-value therapy with potential long-term cost savings through durable remission and reduced disease complications.
An expert discusses how underutilization of combination lipid-lowering therapies stems from overly complex guidelines, primary care providers managing multiple chronic diseases simultaneously, cost and insurance coverage concerns, unfamiliarity with newer medications, and systemic health care barriers. He notes that these issues are particularly problematic when 50% of patients who experienced a heart attack are not even receiving foundational statin therapy 6 months post event.
